RAJAF TFA Therapeutics, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1885680 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-0.6%
TTM net income YoY31.6%
TTM EPS YoY—
Revenue 3-yr CAGR185.9%
Net income 3-yr CAGR—
Margins
Gross margin61.1%
Operating margin-11.3%
Net margin-12.4%
FCF margin—
EBITDA margin-0.5%
Returns
ROE—
ROA-3.3%
ROIC (approx.)—
Asset turnover0.27x
Leverage & solvency
Liabilities / assets111.5%
Debt / equity—
Current ratio0.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.23x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.25M | $1.25M | $882,533 | $53,304 | $879,318 |
| Cost of revenue | $484,607 | $347,004 | $116,146 | $13,746 | $1.06M |
| Gross profit | $760,741 | $906,480 | $766,387 | $39,558 | -$176,212 |
| R&D expense | — | — | — | $118,444 | $25,052 |
| SG&A expense | — | — | $538,554 | $336,235 | $94,335 |
| Operating income | -$141,128 | -$183,913 | $227,833 | -$415,121 | -$119,387 |
| Interest expense | — | — | $26,535 | $71,772 | $12,350 |
| Pretax income | -$154,822 | -$191,301 | $190,815 | -$415,111 | -$119,380 |
| Income tax | — | $34,957 | $21,530 | $792 | $351 |
| Net income | -$154,822 | -$226,258 | $751,609 | -$720,093 | -$491,006 |
| EBITDA | -$5,885 | $223,352 | $284,590 | -$390,631 | $29,851 |
| EPS (basic) | 0.00 | 0.00 | 0.01 | -0.01 | -4.91 |
| EPS (diluted) | 0.00 | 0.00 | 0.01 | -0.01 | -4.91 |
| Weighted avg. shares (diluted) | 111.12M | 111.12M | 111.12M | 104.42M | 100,000 |
| Banking | |||||
| Loans, net | — | — | — | — | $148.90B |
| Balance sheet | |||||
| Cash & equivalents | $3,199 | $37,284 | $23,104 | $6,628 | $99,487 |
| Receivables | — | $305 | — | $149,510 | $358,006 |
| Inventory | $674,196 | — | — | $313,530 | $480,352 |
| Current assets | $997,742 | $601,602 | $327,175 | $501,552 | $1.13M |
| PP&E, net | $3.63M | $3.91M | $2.81M | $75,510 | $1.71M |
| Total assets | $4.66M | $4.62M | $3.35M | $2.10M | $3.26M |
| Current liabilities | $5.19M | $4.99M | $2.97M | $2.52M | $2.92M |
| Short-term debt | — | — | — | $57,109 | — |
| Long-term debt | — | — | $431,079 | $414,000 | — |
| Total debt | — | — | $431,079 | $471,109 | — |
| Total liabilities | $5.19M | $5.00M | $3.50M | $3.06M | $3.54M |
| Shareholders' equity | -$534,551 | -$375,543 | -$151,796 | -$951,334 | -$275,813 |
| Net debt | — | — | $407,975 | $464,481 | — |
| Shares outstanding | 111.12M | 111.12M | 111.12M | 111.12M | 111.12M |
| Cash flow statement | |||||
| Operating cash flow | -$35,845 | $312,006 | $359,724 | -$321,378 | -$365,363 |
| Capital expenditure | — | $349,237 | $319,487 | $475 | $100,000 |
| Free cash flow | — | -$37,231 | $40,237 | -$321,853 | -$465,363 |
| Investing cash flow | — | -$305,637 | -$319,820 | -$475 | -$110,815 |
| Financing cash flow | — | — | -$32,208 | $245,787 | $574,504 |
| Depreciation & amortization | $135,243 | $407,265 | $56,757 | $24,490 | $149,238 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.